Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on International Business Watch.
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key appointments in business development...
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H...
Brookfield Business Partners Reports Third Quarter 2025 Results
BROOKFIELD, NEWS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Brookfield Business Partners (NYSE: BBU, BBUC; TSX: BBU.UN, BBUC) announced today financial results for the quarter ended September 30, 2025. “We made excellent progress in our business over the...
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million Separately announced upcoming retirement of...
Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
Initiated full U.S. commercial launch of AYON Body Contouring System™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include power liposuction Increased total...
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia...
LENSAR® Reports Third Quarter 2025 Results and Provides Business Update
18 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla.,...
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 with...
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer,...
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered...
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
Engagement with FDA on GH001 IND complete response ongoing Full dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025 Long-term clinical data on safety and efficacy from Open-Label Extension presented at ECNP in October...
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected in the first half of 2027...
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1...
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data...
Wood's Exterior Cleaning Services Wins the 2025 Quality Business Award for Best Window Cleaners in Kingston upon Hull
KINGSTON UPON HULL, UNITED KINGDOM, November 6, 2025 /EINPresswire.com/ -- Wood's Exterior Cleaning Services has been named the recipient of the 2025 Quality Business Award for The Best Window Cleaners in Kingston upon Hull, UK. This marks the...
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of...
Aspen Aerogels, Inc. Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Full-year 2025 outlook updated to reflect lower near-term EV production in North America PyroThin® award from a major EU OEM demonstrates technology leadership & supports growth opportunities LNG and Subsea project opportunities expected to drive...
Nitrogenous Fertilizer Market Report 2025| Business Growth, Development Factors, Current And Future Trends till 2029
The Business Research Company's Nitrogenous Fertilizer Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, November 6, 2025 /EINPresswire.com/ -- How Much Is The Nitrogenous...
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL®...